Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
startups
vc
7
×
boston blog main
national top stories
san francisco blog main
boston top stories
new york blog main
biotech
new york top stories
san francisco top stories
boston
deals
san diego blog main
san diego top stories
fda
financing
gene therapy
ipo
national
sanofi
venture capital
accent therapeutics
acetylon pharmaceuticals
aducanumab
akili interactive labs
alnylam
alnylam pharmaceuticals
alzheimer's disease
amblyotech
ambys medicines
amy schulman
andreas klein
anna greka
arena pharmaceuticals
artie suckow
asklepios biopharmaceutical
azacitidine
barry greene
What
medicines
7
×
new
diseases
bio
biotech
developing
drugs
field
gene
launch
rna
startup
therapeutics
activity
advance
aiming
aims
ambys
announced
approach
approvals
aren’t
backs
based
bets
big
biogen
biologics
called
car
clamped
click
considered
control
covid
create
crispr
cutting
deadly
deal
Language
unset
Current search:
medicines
×
vc
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”